Drug Trial Radar · NCT06669754
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Dec 1, 2024
Primary completion
Jul 21, 2026
Study completion Jul 21, 2026
Sponsor
- Lead sponsor
- Pharvaris Netherlands B.V.Industry
- Sponsor type
- Industry
- First posted
- Nov 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.
Conditions
- Hereditary Angioedema (HAE)
Interventions
DeucrictibantDrug
Deucrictibant 40mg extended-release tablet for once daily oral use
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-normalized (per 4 weeks) number of Investigator-confirmed HAE attacks during the 24-week Treatment PeriodTime frame: 24 weeks
Locations
56 sites in 24 countries. Site status is shown where the registry gives one.
Study Site
Little Rock, Arkansas
Study Site
San Diego, California
Study site
Santa Monica, California
Study site
Walnut Creek, California
Study Site
Chevy Chase, Maryland
Study Site
St Louis, Missouri
Study Site
Corrientes, Argentina
Study Site
San Martin, Argentina
Study Site
Santo André, Brazil
Study Site
Sofia, Bulgaria
Study Site
Sofia, Bulgaria
Study Site
Edmonton, Canada
Study Site
Ottawa, Canada
Study Site
Grenoble, France
Study Site
Lille, France
Study Site
Berlin, Germany
Study Site
Frankfurt, Germany
Study Site
Hanover, Germany
Study Site
Hong Kong, Hong Kong
Study Site
Budapest, Hungary
Study Site
Dublin, Ireland
Study Site
Milan, Italy
Study Site
Padova, Italy
Study Site
Kawasaki, Japan
Study Site
Tokyo, Japan
Study Site
Tokyo, Japan
Study Site
Auckland, New Zealand
Study Site
Krakow, Poland
Study Site
San Juan, Puerto Rico
Study Site
Sângeorgiu de Mureş, Romania
Study Site
Singapore, Singapore
Study Site
Martin, Slovakia
Study Site
Cape Town, South Africa
Study Site
Daegu, South Korea
Study Site
Seoul, South Korea
Study Site
Seoul, South Korea
Study Site
Suwon, South Korea
Study Site
Barcelona, Spain
Study Site
Barcelona, Spain
Study Site
Seville, Spain
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.